Phase
Condition
Renal Cell Carcinoma
Kidney Cancer
Renal Cell Cancer
Treatment
an AI-based real-time image-guided kidney model system
Clinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Ages 18-80 years, regardless of gender
Written informed consent obtained from the patient or legally authorizedrepresentative after full protocol disclosure
Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renaltumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score ≤10)
Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023)
Elective minimally invasive partial nephrectomy (laparoscopic/robotic) aftercomprehensive surgical counseling
Exclusion
Exclusion Criteria:
Multifocal renal tumors (bilateral or unilateral)
Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy)within 6 months
Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy)
Intraoperative conversion to radical nephrectomy or open approach
Postoperative adjuvant therapy during protocol-defined follow-up (12 months)
Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR <30 mL/min/1.73m²)affecting outcome assessment
Concurrent enrollment in interventional clinical trials
Investigator-determined ineligibility based on risk-benefit analysis
Study Design
Study Description
Connect with a study center
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
Nanjing, Jiangsu 210036
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.